[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1998022141A3 - Effets renforces pour therapeutique associee a l'haptene - Google Patents

Effets renforces pour therapeutique associee a l'haptene Download PDF

Info

Publication number
WO1998022141A3
WO1998022141A3 PCT/US1997/018475 US9718475W WO9822141A3 WO 1998022141 A3 WO1998022141 A3 WO 1998022141A3 US 9718475 W US9718475 W US 9718475W WO 9822141 A3 WO9822141 A3 WO 9822141A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhanced effects
hapten conjugated
conjugate
half life
vivo half
Prior art date
Application number
PCT/US1997/018475
Other languages
English (en)
Other versions
WO1998022141A2 (fr
Inventor
Roland Buelow
Alexander R Lussow
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Priority to AU72983/98A priority Critical patent/AU7298398A/en
Priority to EP97949336A priority patent/EP1027073A2/fr
Publication of WO1998022141A2 publication Critical patent/WO1998022141A2/fr
Publication of WO1998022141A3 publication Critical patent/WO1998022141A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention a trait à de nouvelles méthodes permettant de renforcer la demi-vie efficace in vivo de composés thérapeutiques chez des mammifères. Plus particulièrement, ces composés thérapeutiques sont associés à une fraction haptène. A la suite de l'administration au mammifère, les conjugats - composé thérapeutique/haptène - sont fixés par des anticorps circulant dirigés de manière spécifique contre la fraction haptène du conjugat, ce qui se solde par une stabilisation du conjugat dans le système vasculaire et une augmentation réelle de la demi-vie in vivo du composé thérapeutique.
PCT/US1997/018475 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene WO1998022141A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU72983/98A AU7298398A (en) 1996-11-19 1997-11-06 Enhanced effects for hapten conjugated therapeutics
EP97949336A EP1027073A2 (fr) 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75267196A 1996-11-19 1996-11-19
US08/752,671 1996-11-19

Publications (2)

Publication Number Publication Date
WO1998022141A2 WO1998022141A2 (fr) 1998-05-28
WO1998022141A3 true WO1998022141A3 (fr) 1999-01-07

Family

ID=25027301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018475 WO1998022141A2 (fr) 1996-11-19 1997-11-06 Effets renforces pour therapeutique associee a l'haptene

Country Status (3)

Country Link
EP (1) EP1027073A2 (fr)
AU (1) AU7298398A (fr)
WO (1) WO1998022141A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01003770A (es) 1998-10-13 2002-05-06 Univ Georgia Res Found Peptidos bioactivos estabilizados, y metodos de identificacion, sintesis y uso de los mismos.
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2001032207A1 (fr) * 1998-10-30 2001-05-10 United States Army Medical Research And Materiel Command Procede permettant d'appliquer une immunotherapie active/passive
EP1757701A1 (fr) * 1999-12-24 2007-02-28 Genentech, Inc. Procédés et compositions pour la prolongation de la demi-vie d'élimination des composés bioactifs
DE60030323T2 (de) * 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
EP2428226A1 (fr) 2001-10-22 2012-03-14 The Scripps Research Institute Composés de ciblage d'anticorps
EP2949668B1 (fr) 2005-05-18 2019-08-14 Ablynx N.V. Nanobodies tm améliorés contre le facteur alpha de la nécrose des tumeurs
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2102244A2 (fr) 2006-12-19 2009-09-23 Ablynx N.V. Séquences d'acides aminés dirigées contre une métalloprotéinase de la famille adam et polypeptides les comprenant à des fins de traitement de maladies et troubles liés à adam
EP2260058A2 (fr) 2008-04-07 2010-12-15 Ablynx N.V. Séquences d acides aminés dirigées contre les voies notch et leurs utilisations
WO2010010119A1 (fr) 2008-07-22 2010-01-28 Ablynx Nv Séquences d’acides aminés dirigées contre des récepteurs de désactiveurs multicibles et polypeptides
BRPI1013877A2 (pt) 2009-04-10 2017-08-15 Ablynx Nv Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
SI2438087T1 (sl) 2009-06-05 2017-10-30 Ablynx N.V. Trivalnentni konstrukti nanoteles proti humanemu respiratornemu sincicijskemu virusu (HRSV) za preventivo in/ali zdravljenje okužb dihalnih poti
WO2011064382A1 (fr) 2009-11-30 2011-06-03 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
WO2011073180A1 (fr) 2009-12-14 2011-06-23 Ablynx N.V. Anticorps à domaine variable unique dirigés contre ox4ql, produits de recombinaison et utilisation thérapeutique
WO2011083140A1 (fr) 2010-01-08 2011-07-14 Ablynx Nv Domaines variables simples d'immunoglobuline dirigés contre le cxcr4 doués d'une meilleure activité thérapeutique et produits de recombinaison les comprenant
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
TWI619811B (zh) 2010-11-08 2018-04-01 諾華公司 趨化細胞素受體結合多肽
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2723772A1 (fr) 2011-06-23 2014-04-30 Ablynx N.V. Domaines variables uniques d'immunoglobuline dirigés contre ige
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2014087010A1 (fr) 2012-12-07 2014-06-12 Ablynx N.V. Polypeptides améliorés dirigés contre ige
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
CA3043515A1 (fr) 2016-11-16 2018-05-24 Ablynx Nv Polypeptides de recrutement de lymphocytes t capables de se lier a cd123 et tcr alpha/beta
EP3630818A1 (fr) 2017-06-02 2020-04-08 Ablynx NV Immunoglobulines liant l'aggrécane
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
SG11202006674QA (en) 2018-03-30 2020-08-28 Nanjing Legend Biotech Co Ltd Single-domain antibodies against lag-3 and uses thereof
US20240228593A9 (en) 2021-02-19 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017699A1 (fr) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Regulation de l'activite de lymphocytes a l'aide de peptides hla
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
WO1995034321A1 (fr) * 1994-06-16 1995-12-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation immunitaire a l'aide de fragments de chaine alpha de classe ii
WO1996035443A1 (fr) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Traitement destine a inhiber la progression de maladies auto-immunes
WO1997024140A1 (fr) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction de proteines hla avec des membres de la famille hsp70 de proteines
WO1997037690A2 (fr) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Conjugues cytomodulants d'elements de paires de liaison specifiques

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017699A1 (fr) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Regulation de l'activite de lymphocytes a l'aide de peptides hla
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
WO1995034321A1 (fr) * 1994-06-16 1995-12-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation immunitaire a l'aide de fragments de chaine alpha de classe ii
WO1996035443A1 (fr) * 1995-05-12 1996-11-14 Sangstat Medical Corporation Traitement destine a inhiber la progression de maladies auto-immunes
WO1997024140A1 (fr) * 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction de proteines hla avec des membres de la famille hsp70 de proteines
WO1997037690A2 (fr) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Conjugues cytomodulants d'elements de paires de liaison specifiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUELOW R ET AL: "PROLONGATION OF SKIN ALLOGRAFT SURVIVAL IN MICE FOLLOWING ADMINISTRATION OF ALLOTRAP", TRANSPLANTATION, vol. 59, no. 4, 27 February 1995 (1995-02-27), pages 455 - 460, XP000652975 *
LUSSOW A R ET AL: "REDIRECTING CIRCULATING ANTIBODIES VIA LIGAND-HAPTEN CONJUGATES ELIMINATES TARGET CELLS IN VIVO", JOURNAL OF IMMUNOTHERAPY: WITH EMPHASIS ON TUMOR IMMUNOLOGY, vol. 19, no. 4, July 1996 (1996-07-01), pages 257 - 265, XP002050531 *

Also Published As

Publication number Publication date
EP1027073A2 (fr) 2000-08-16
WO1998022141A2 (fr) 1998-05-28
AU7298398A (en) 1998-06-10

Similar Documents

Publication Publication Date Title
WO1998022141A3 (fr) Effets renforces pour therapeutique associee a l'haptene
WO1997029779A3 (fr) Conjugues de egf-genisteine pour le traitement du cancer
ZA964614B (en) Methods for the preparation of substantially monomeric callcheamicin derivative carrier conjugates.
AU2582488A (en) Drug-monoclonal antibody conjugates
ID19188A (id) Metoda untuk menghasilkan asam linoleat konjugasi
EP0911036A3 (fr) Structure immunogene à double vecteur
EP1374908A3 (fr) Conjugués de polymère - médicament comprenant des groupes de liaison hydrazide
FI973002A0 (fi) Terapeuttinen yhdiste - rasvahappokonjugaatit
FR2696176B1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
CA2150925A1 (fr) Synthese amelioree de conjugues polymeriques bioactifs
EP0630260A4 (fr) Conjugues de polysaccharide-proteine.
IL146015A0 (en) Methods for producing 5'-nucleic acid-protein conjugates
AU3076601A (en) Chemically-programmable immunity
TR199902775T2 (xx) 20(S)-Kamptotesin glikokonjugeleri.
MY134690A (en) Antitumor therapy comprising distamycin derivatives.
HUP0001069A3 (en) Method for producing an igm preparation for intravenous administration
CA2098593A1 (fr) Methode de traitement du cancer
DZ1718A1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
AU3991899A (en) Verotoxin b subunit for immunization
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
CA2190867A1 (fr) Procedes pour l'absorption renale reduite de fragments d'anticorps
WO2001040239A3 (fr) Conjugues metal de transition-cyclopentadienyle-tropane
FR2719844B1 (fr) Dérivés de 5,6-dihydro-4h-thiéno[3,4-c]pyrrole, leur préparation et leur application en thérapeutique.
CA2109572A1 (fr) Methode de reduction des effets secondaires de medicaments
FR2697520B1 (fr) Dérivés de benz[e]indende.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1997949336

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWP Wipo information: published in national office

Ref document number: 1997949336

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997949336

Country of ref document: EP